(19)
(11) EP 4 238 960 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
published in accordance with Art. 153(4) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
22.11.2023 Bulletin 2023/47

(43) Date of publication:
06.09.2023 Bulletin 2023/36

(21) Application number: 21886259.7

(22) Date of filing: 27.10.2021
(51) International Patent Classification (IPC): 
C07D(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/4045; A61K 31/437; A61K 31/4439; A61K 31/444; A61K 31/4545; A61K 31/506; A61K 31/5377; A61P 31/14; C07D 209/18; C07D 403/14; C07D 405/12; C07D 405/14; C07D 401/14; C07D 403/04; C07D 409/14; C07D 417/14; C07D 413/14; C07D 471/04; C07D 471/10; C07D 487/04; C07D 491/107; C07D 491/20; C07D 495/10; C07D 519/00
(86) International application number:
PCT/JP2021/039623
(87) International publication number:
WO 2022/092141 (05.05.2022 Gazette 2022/18)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 28.10.2020 JP 2020180856

(71) Applicants:
  • Shionogi & Co., Ltd.
    Osaka-shi, Osaka 541-0045 (JP)
  • UBE Corporation
    Ube-shi, Yamaguchi 755-8633 (JP)

(72) Inventors:
  • OKANO, Azusa
    Osaka-shi, Osaka 541-0045 (JP)
  • TATENO, Yusuke
    Osaka-shi, Osaka 541-0045 (JP)
  • NODU, Kouhei
    Osaka-shi, Osaka 541-0045 (JP)
  • SUZUKI, Shinji
    Osaka-shi, Osaka 541-0045 (JP)
  • AKIYAMA, Toshiyuki
    Osaka-shi, Osaka 541-0045 (JP)
  • MATOYAMA, Masaaki
    Ube-shi, Yamaguchi 755-8633 (JP)
  • AKAZA, Hiroto
    Ube-shi, Yamaguchi 755-8633 (JP)
  • FUKUDA, Takashi
    Ube-shi, Yamaguchi 755-8633 (JP)

(74) Representative: Vossius & Partner Patentanwälte Rechtsanwälte mbB 
Siebertstraße 3
81675 München
81675 München (DE)

   


(54) AMIDE DERIVATIVE HAVING ANTIVIRAL ACTIVITY


(57) The present invention provides a compound represented by formula (I) :

wherein the dashed line indicates the presence or absence of a bond; R1 is carboxy or the like; L is substituted or unsubstituted non-aromatic carbocyclyldiyl or the like; R2 is substituted or unsubstituted alkyl; R3 is a hydrogen atom or the like; X is =CRX-or =N-; Y is =CRY- or =N-; U is -CRU= or -N=; V is -CRV= or -N=; W is =CRW- or =N-; ZA is -C= or -N-; ZB is -CR5R6- or the like; ZC is -CR7R8- or the like; RX, RY, RV and RW are each independently a hydrogen atom or the like; RU is a hydrogen atom or the like; R5 and R6 are each independently a hydrogen atom or the like; R7 and R8 are each independently a hydrogen atom or the like; R4 is substituted or unsubstituted alkyloxy or the like,
or a pharmaceutically acceptable salt thereof, having an antiviral activity; and a pharmaceutical composition comprising the same.